Wiktoria Oczkowska

Mrs. Wiktoria Oczkowska

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KOKlaudia Ostrowicz
Klaudia Ostrowicz
DBDominika Brzuchacz
Dominika Brzuchacz
JBJoanna Borkowska
Joanna Borkowska
DFDawid Furtek
Dawid Furtek
ADAleksandra Duda
Aleksandra Duda
KOKrzysztof Ożóg
Krzysztof Ożóg
Introduction Electrocardiography (ECG) remains a fundamental diagnostic tool in pediatric cardiology; however, its interpretation is challenging because normal electrocardiographic parameters vary considerably with age and cardiovascular maturation. The development of artificial intelligence (AI), particularly machine learning and deep learning, has created new possibilities for automated ECG analysis and the detection of subtle patterns that may be difficult to identify using conventional interpretation. This review aims to summarize current applications of AI in pediatric electrocardiography, with particular emphasis on diagnostic and predictive applications and their clinical potential. Current State of Knowledge Current evidence indicates that AI-based models can support the automated interpretation of pediatric ECGs and the detection of rhythm and conduction disorders, including Wolff-Parkinson-White syndrome, long QT syndrome, and congenital heart disease. Deep learning models have also demonstrated the ability to estimate corrected QT intervals and to identify ECG patterns associated with left ventricular dysfunction, hypertrophy, and dilation. Beyond conventional diagnosis, AI-ECG has shown potential for prognostic applications, including the prediction of adverse cardiovascular events in children. These findings suggest that AI models can extract complex information from ECG recordings beyond individual conventional parameters. However, the available evidence remains limited by relatively small and heterogeneous pediatric datasets, age-related variability in ECG characteristics, data heterogeneity, limited external validation, and the predominance of retrospective studies. Moreover, evidence regarding the impact of AI-ECG on clinical decision-making and patient outcomes remains limited. Conclusions AI represents a promising approach to expanding the diagnostic and prognostic potential of pediatric electrocardiography. Current findings support its role as a tool for automated ECG interpretation, disease detection, risk stratification, and indirect assessment of cardiac structure and function. Nevertheless, AI-ECG should currently be regarded as a clinical decision-support tool rather than a replacement for conventional cardiac assessment. Further multicenter, prospective, and externally validated studies are needed to establish the generalizability, safety, interpretability, and clinical utility of AI-based ECG models in pediatric practice.

28 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
PDPrzemysław Dominik Drabik
Przemysław Dominik Drabik
DMDiana Morawska
Diana Morawska
APAleksandra Katarzyna Pelczar
Aleksandra Katarzyna Pelczar
WOWiktoria Oczkowska
Wiktoria Oczkowska
AMAlex Malinowski
Alex Malinowski
MWMonika Waszak
Monika Waszak
Background: Schizophrenia is a chronic mental illness affecting over 23 million people worldwide. Current pharmacotherapy, primarily based on dopamine D₂ receptor antagonism, is associated with significant adverse effects - including extrapyramidal symptoms, metabolic disturbances, and hyperprolactinemia - and up to 30% of patients show inadequate response. Aim: This review aims to present and synthesize the available evidence on xanomeline–trospium (Cobenfy®) - the first approved antipsychotic with a predominantly muscarinic mechanism of action - as a novel therapeutic option for schizophrenia. Methods: A narrative literature review was conducted in PubMed, Scopus, Web of Science, and Google Scholar databases up to June 2026, focusing on peer‑reviewed articles, clinical trials, and systematic reviews on xanomeline–trospium in schizophrenia. Results: Xanomeline–trospium demonstrated significant antipsychotic efficacy across the Phase 2 and Phase 3 EMERGENT trials, with moderate‑to‑large effect sizes (Cohen's d = 0.60). The safety profile is distinctly favorable: no extrapyramidal symptoms, weight gain, metabolic disturbances, or prolactin elevation were observed. Gastrointestinal adverse events (nausea, vomiting, constipation) were the most common but were generally mild, transient, and occurred early in treatment. Long‑term open‑label extension studies confirmed sustained efficacy and safety over 52 weeks, with ecological momentary assessment data indicating improvements in real‑world social functioning and positive affect. Conclusions: Xanomeline–trospium represents a promising alternative for schizophrenia treatment, particularly for patients intolerant to conventional antipsychotics or those with metabolic comorbidities. Its novel mechanism and favorable tolerability profile position it as a significant advancement in psychopharmacology. Further research is needed to clarify its role in treatment‑resistant schizophrenia and to confirm long‑term outcomes in diverse populations.

Verified
Journal Article
Open access
PDF file
WOWiktoria Oczkowska
Wiktoria Oczkowska
APAleksandra Katarzyna Pelczar
Aleksandra Katarzyna Pelczar
KGKinga Głodek
Kinga Głodek
Zaneta Kimber-TrojnarZaneta Kimber-Trojnar
Zaneta Kimber-Trojnar
Gene therapy has emerged as a promising approach for the treatment and prevention of genetic disorders through targeted modification of cellular DNA. The clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) system, in particular, has enabled precise correction of disease-causing mutations. Recently, increasing interest has been directed toward in utero gene therapy, which offers a unique therapeutic window to prevent irreversible pathological changes before birth. This narrative review explores the current preclinical landscape of in utero CRISPR-Cas9-mediated genome editing. A literature search was conducted using PubMed/MEDLINE and Google Scholar databases to identify relevant studies, focusing primarily on delivery strategies, temporal considerations, therapeutic efficacy, and safety outcomes. Preclinical evidence demonstrates that prenatal delivery of CRISPR-Cas9 components in animal models can achieve durable genome editing in multiple fetal tissues, leading to phenotypic improvements in metabolic and early-onset lethal disorders. However, significant challenges remain, including off-target effects, mosaicism, maternal–fetal immune interactions, and the risk of unintended germline transmission. Ultimately, while in utero CRISPR-Cas9 gene therapy holds substantial therapeutic potential for severe congenital pathologies, rigorous safety evaluation, delivery optimization, and resolution of ethical and regulatory dilemmas are strictly required before clinical translation can be considered.

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KOKlaudia Ostrowicz
Klaudia Ostrowicz
DBDominika Brzuchacz
Dominika Brzuchacz
AMAlex Malinowski
Alex Malinowski
APAleksandra Katarzyna Pelczar
Aleksandra Katarzyna Pelczar
WOWiktoria Oczkowska
Wiktoria Oczkowska
JBJoanna Borkowska
Joanna Borkowska
Introduction Insulin resistance is a complex metabolic disorder that plays a pivotal role in the pathogenesis of type 2 diabetes, metabolic syndrome, and cardiovascular diseases. Given its increasing prevalence, growing attention is being directed toward non-pharmacological interventions such as low glycemic index (LGI) diets and regular physical activity. The objective of this study was to compare the effects of an LGI diet and physical activity on the management of insulin resistance. Current State of Knowledge A review of scientific literature published between 2020 and 2025 was conducted using PubMed, Scopus, and Google Scholar databases. Both original research articles and review papers focusing on the impact of LGI diets and physical activity on insulin resistance were included. The findings indicate that both LGI diets and regular physical activity positively influence glycemic parameters by enhancing tissue sensitivity to insulin and reducing blood glucose and insulin concentrations. The combination of these interventions yields superior therapeutic outcomes compared to each intervention alone. The effectiveness of combined strategies also appears to be influenced by the timing and type of physical exercise. Conclusions A multifaceted approach integrating an LGI diet with physical activity constitutes an effective strategy for managing insulin resistance. Given the multifactorial nature of insulin resistance, treatment should be individually tailored and monitored by healthcare professionals. Further research is warranted to account for variables such as sex, age, and duration of the intervention.

14 April 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
WOWiktoria Oczkowska
Wiktoria Oczkowska
DMDiana Morawska
Diana Morawska
PDPrzemysław Dominik Drabik
Przemysław Dominik Drabik
AMAlex Malinowski
Alex Malinowski
KMKlaudia Marchewka
Klaudia Marchewka
KBKacper Bartosik
Kacper Bartosik
Background. Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain and altered bowel habits, involving gut–brain axis dysregulation, psychosocial, and immune mechanisms. Insomnia and sleep disturbances are highly prevalent in IBS and may contribute to symptom burden, but their role remains unclear. Aim. To systematically review the role of insomnia in IBS, focusing on prevalence, symptom severity, mechanisms, and effects of sleep-targeted interventions. Methods. A comprehensive literature search (including PubMed) was conducted for studies published up to 2026. Observational studies, clinical trials, mechanistic studies, and reviews examining the relationship between insomnia and IBS were included. Data on study design, populations, sleep assessment, IBS criteria, and outcomes were extracted. Due to heterogeneity, a qualitative synthesis was performed. Results. Insomnia is more prevalent in IBS patients than controls (37–70%). Greater insomnia severity is associated with increased abdominal pain, bloating, bowel disturbances, and reduced quality of life. Longitudinal and genetic evidence suggests insomnia may be an independent risk factor for IBS onset and exacerbation. Proposed mechanisms include gut–brain axis dysregulation, visceral hypersensitivity, stress response alterations, and immune modulation. Subjective sleep disturbances appear particularly predictive of symptom severity. Behavioral interventions, such as cognitive-behavioral therapy for insomnia (CBT-I), show potential to improve both sleep and IBS symptoms, though current evidence is limited. Conclusions. Insomnia is a common and clinically relevant factor in IBS, acting as both a comorbidity and a modifier of disease severity. Integrating sleep assessment and management into IBS care may improve outcomes. Further large-scale and mechanistic studies are needed to clarify causality and optimize treatment strategies.